8-K: Kintara Therapeutics and TuHURA Biosciences Announce Merger to Advance Novel Cancer Therapies

Kintara Therapeutics and TuHURA Biosciences have agreed to merge, creating a company focused on advancing personalized cancer vaccines and bi-functional antibody drug conjugates.

Summary

• Kintara Therapeutics and TuHURA Biosciences have entered into a definitive merger agreement.
• The combined company will focus on advancing TuHURAs personalized cancer vaccines and bi-functional ADCs.
• TuHURAs IFx-2.0 is expected to enter a Phase 3 trial as adjunctive therapy with Keytruda for advanced Merkel cell carcinoma in the second half of 2024.
• TuHURA has a $31 million subscribed financing in connection with the merger agreement, expected to fund operations through late 2025.
• The combined company is expected to operate under the name TuHURA Biosciences, Inc. and trade on Nasdaq under the ticker HURA.
• On a pro forma basis, Kintara equity holders are expected to own approximately 2.85% of the combined company, or 5.45% including CVR shares, while TuHURA equity holders are expected to own approximately 97.15%, or 94.55% including CVR shares.
• Kintara stockholders will receive a Contingent Value Right (CVR) entitling them to additional shares upon the enrollment of 10 patients in a REM-001 study and completion of 8 weeks of follow-up.
• The merger is expected to close in the third quarter of 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the merger, highlighting the potential of the combined company's pipeline and the financial resources secured. The focus on overcoming resistance to immunotherapy is a significant positive, and the Phase 3 trial for IFx-2.0 is a key milestone. However, the relatively small ownership stake for Kintara shareholders and the contingent nature of the CVR temper the overall optimism.

Positives

• The merger creates a company with a risk-diversified late-stage oncology pipeline.
• TuHURAs IFx technology has shown the ability to produce durable systemic anti-tumor responses in patients who failed checkpoint inhibitors.
• TuHURAs bi-functional ADCs target MDSCs, which are responsible for creating an immunologic sanctuary for tumors.
• The $31 million subscribed financing is expected to provide a cash runway into late 2025.
• The combined company will have a focus on overcoming resistance to current immunotherapies.

Negatives

• Kintara equity holders will have a relatively small ownership stake in the combined company.
• The CVR is contingent on the success of a REM-001 study, with no guarantee of payment.
• The merger is subject to stockholder approval and other customary closing conditions.

Risks

• The merger may not be completed if conditions are not met, including stockholder approval.
• There are uncertainties regarding the timing of the merger and the ability of both companies to complete the transaction.
• The combined company may not be able to accurately estimate operating expenses or manage cash resources effectively.
• The combined company may face challenges in protecting intellectual property rights and responding to competitive pressures.
• The combined company may not be successful in developing and commercializing its drug candidates.

Future Outlook

The combined company will focus on advancing TuHURAs personalized cancer vaccines and bi-functional ADCs, with a Phase 3 trial for IFx-2.0 expected to begin in the second half of 2024 and a cash runway into late 2025.

Management Comments

• Robert E. Hoffman, Kintaras President and Chief Executive Officer, stated that the merger with TuHURA represents the best path forward for Kintara stockholders and has the potential to deliver near and long-term value.
• Dr. James Bianco, President and Chief Executive Officer of TuHURA, commented that the merger will allow the combined company the flexibility to focus resources on advancing IFx-2.0 to market and other drug candidates toward human clinical trials.

Industry Context

The merger reflects a trend in the biopharmaceutical industry to combine resources and expertise to advance novel therapies, particularly in the immuno-oncology space, where there is a high unmet need for treatments that can overcome resistance to current therapies.

Comparison to Industry Standards

• The focus on personalized cancer vaccines and bi-functional ADCs aligns with the industry's shift towards more targeted and effective immunotherapies.
• The Phase 3 trial for IFx-2.0 in Merkel cell carcinoma is a significant step, as it targets a specific patient population with a high unmet need.
• The $31 million subscribed financing is a substantial amount that should provide the combined company with a runway to achieve key milestones.
• The use of the FDA's accelerated approval pathway is a strategic move to expedite the potential approval of IFx-2.0.
• The development of bi-functional ADCs targeting MDSCs is a novel approach that could address a major challenge in cancer immunotherapy.

Management Changes

Corporate Governance

Stakeholder Impact

• Kintara stockholders will receive a CVR and a small ownership stake in the combined company.
• TuHURA stockholders will have a majority ownership stake in the combined company.
• Employees of both companies will be integrated into the new organization.
• Patients may benefit from the development of new cancer therapies.
• The combined company will have a focus on overcoming resistance to current immunotherapies.

Next Steps

• Obtain stockholder approval for the merger.
• Complete the merger transaction.
• Initiate the Phase 3 trial for IFx-2.0 in Merkel cell carcinoma in the second half of 2024.
• Advance the development of bi-functional ADCs.
• Continue the REM-001 study and seek out-licensing or acquisition opportunities.
• Begin a basket trial across several cancers like ovarian and triple negative breast cancer among patients whose tumors exhibit primary resistance to checkpoint inhibitor therapy later this year.
• Advance IFx-3.0 to IND-enabling studies and first in human phase 1 testing by late 2025.

Key Dates

Keywords

merger, immuno-oncology, cancer vaccines, antibody drug conjugates, checkpoint inhibitors, Merkel cell carcinoma, REM-001, TuHURA Biosciences, Kintara Therapeutics, clinical trials